New trial data do not end the PSA screening debate.
Vastag
Brian
B
D000328:Adult; D000367:Age Factors; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D002986:Clinical Trials as Topic; D015897:Comorbidity; D003657:Decision Making; D005060:Europe / Q000453:epidemiology; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000009:adverse effects / Q000379:methods / Q000592:standards; D008875:Middle Aged; D010358:Patient Participation; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000401:mortality* / Q000628:therapy; D013997:Time Factors; D014481:United States / Q000453:epidemiology
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen